Insights

Home » Insights » Insights Intercept Blood System
    11/2018- Transfusion-Transmitted Infections

    Platelet transfusion-associated bacterial sepsis cases reported in Utah and California

    The US Department of Health and Human Services, Centers for Disease Control (CDC) recently published details related to fatal sepsis cases that resulted from bacterially contaminated conventional platelet components.

    08/2018- Regulations

    Pathogen Inactivation, towards becoming the standard of care in Germany

    As of January 1, 2018, specific reimbursement for pathogen inactivated platelets is now available in Germany.


    08/2018- Cerus

    Madrid adopts INTERCEPT™

    On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPT Blood System for platelets.


    08/2018- Cerus

    EFS adopts INTERCEPT

    The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).


    08/2018- Economics

    INTERCEPT Blood System further expands with  the TS  multidose set (video)

    In Europe, 40% of all platelet concentrates undergo either bacterial screening or pathogen inactivation. This percentage may increase even more in 2018 as major European countries are currently taking action to mitigate the risk of septic transfusion reactions and emerging pathogens. 


    08/2018- Cerus

    Let us do something about it!

    In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.